首页> Clinical rheumatology> Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection

Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection

导出原文传递

翻译打印收藏纠错

第一作者： Liu, Suling

作者： Liu, Suling ^[1] ; He, Ziye ^[2] ; Wu, Wenjing ; Jin, Hua ; Cui, Yang

作者单位： Shantou University,Shantou Univ ^[1] Guangdong Academy of Medical Sciences & Guangdong General Hospital,Southern Med Univ ^[2]

关键词 Axial spondyloarthritis Hepatitis B virus infection Latent tuberculosis infection Reactivation Safety Secukinumab

发布时间 2023-10-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Clinical rheumatology

2023年42卷9期

2369-2376页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Clinical rheumatology

2023年42卷9期

2369-2376页

检索历史清除

Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection

Clinical rheumatology

相似文献

同项目论文

Clinical rheumatology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection

Clinical rheumatology

相似文献

同项目论文

Clinical rheumatology

相关期刊

检索历史清除